Organization
University Hospital Brno
5 abstracts
Abstract
Observation vs. radiotherapy in primary mediastinal B-cell lymphoma patients with complete response to standard immunochemotherapy: The IELSG37 randomized trial.Org: Oncology Institute of Southern Switzerland, Institute of Oncology Research, Università della Svizzera italiana, Bellinzona, Switzerland, University of Southampton,
Abstract
Phase 3 study results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) versus VRd for transplant-ineligible patients with newly diagnosed multiple myeloma (IMROZ).Org: University of Lille, CHU Lille - Hopital Huriez, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Service d'Hématologie et Thérapie Cellulaire,
Abstract
ASC4FIRST, a pivotal phase 3 study of asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS TKIs) in newly diagnosed patients (pts) with chronic myeloid leukemia (CML): Primary results.Org: South Australian Health and Medical Research Institute, Universitätsklinikum Jena, Akita University Hospital, The University of Texas MD Anderson Cancer Center, University of Chicago,
Abstract
Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM).Org: Princess Margaret Cancer Centre, Ankara University, University Hospital Brno, General Hospital Evangelismos, Athens, Greece, St. Vincent's Hospital Melbourne,
Abstract
Comprehensive genomic profiling and individual therapeutic planning in high-risk/refractory pediatric solid tumors: A single-center real-world study.Org: Masaryk University, Faculty of Medicine, Cairo University, CEITEC, Brno, Czech Republic, Czech Republic,